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NANOTUBES AS MITOCHONDRIAL
UNCOUPLERS

above), these nanotubes alloW speci?c conductance (i.e.,
uncoupling threshold and resistance to proton How) of the

CROSS-REFERENCE TO RELATED
APPLICATION

nanotubes. The template method further alloWs lining or coat
ing the inside and outside of the nanotubes With any desired
materials.

Template synthesis of nanotubes generally involves the
deposition of materials (e.g., gold, alumina, silica etc.) into

This application claims priority under 35 U.S.C. §119 to
US. Provisional Application No. 60/678,355 entitled
NANOTUBES AS MITOCHONDRIAL UNCOUPLERS,
?led May 6, 2005, the entire content of Which is hereby

the cylindrical pores of mass-produced track-etched mem

branes (e.g., Coming Corp; Osmonics). Once the nanotubes
are formed Within the membrane pores, the membrane can be

dissolved and the nanotubes can be captured via ?ltration. By

incorporated by reference.

altering the conditions during preparation (e.g., reducing the
plating time When using the electroless plating method for
creating gold nanotubes increases the inner diameter of the
nanotube accordingly) the internal diameter, length and con

FIELD OF THE INVENTION
The present invention relates to nanotubes as mitochon

drial uncouplers. The present invention provides methods of

tents of the nanotube can be controlled as speci?ed.

mitochondrial uncoupling as Well as methods of treating dis

According to another embodiment, nanotubes made of
metals and/or polymers are used to safely uncouple mito

ease conditions and increasing Weight loss by administering

chondria, raise metabolism, and promote Weight loss.

the nanotubes.
20

tially easily, and Wherein the mitochondria have a length of

It is knoWn that mitochondria control metabolism in indi

about 1000-5000 nm and the bilipid membrane of the mito

vidual cells by burning sugars and fats. Mitochondria produce
a membrane potential of about 200 mV across their inner

25

membrane by the active translocation of protons from the
matrix of the mitochondria (the inside) into the inner mem

high potential is applied (about 130-150 mV), Which is only
30

found across the mitochondrial inner membrane in mammal
cells.
In a further embodiment, the interior surface of the non
carbon based nanotubes can be doped With compounds of

35

off When a speci?c pH is reached. This alloWs us to take

Which takes electrons from a high energy state to a loWer

energy resulting in the reduction of oxygen to Water, hence
the term mitochondrial respiration since oxygen is consumed
by this process. The energy released as electrons are taken
from a high energy state to a loWer energy state is used by this

chondria is about 8-10 nm thick.
According to a further embodiment, the nanotubes can be

active only in the mitochondria. This is due to the fact that the
nanotubes only act as proton channels When a signi?cantly

brane space (mitochondria have an inner an outer membrane

as illustrated in FIG. 2). The translocation of protons from the
matrix is due to the activity of the electron transport system,

According to another embodiment, the nanotubes have a
length of about 8-12 nm and a diameter of about 1-3 nm,
Wherein the nanotubes can cross cell membranes substan

BACKGROUND

speci?c pKa such that the non-carbon based nanotube shuts

electron transport system to translocate (i.e., pump) the pro

advantage of the fact that mitochondria have a pH gradient

tons from the matrix to the inner membrane space resulting in
a separation of charge (i.e., membrane potential) as Well as a
pH gradient across the inner membrane due to the movement

across the inner membrane as a result of the pumping of
protons from the matrix across the inner membrane via the

of these protons.
The mitochondrial membrane potential is then “coupled”
to the controlled How of protons back into the matrix through
the ATP synthase Which uses this How to phosphorylate
adenosine diphosphate (“ADP”) to ATP.
Chemical uncouplers of mitochondria have been used to
increase the bodies basal metabolism to encourage Weight
loss. HoWever, chemical uncouplers are readily toxic, as they

electron transport system.
40

In one embodiment, the nanotubes act as proton channels

speci?cally in the mitochondria. The nanotubes acting as
proton channels cause a reduction in mitochondrial mem

45

brane potentials Which in turn increases basal metabolism,
decreases reactive oxygen species (“ROS”), and decreases
detrimental loading of Ca2+ into mitochondria. The reason for
this is that all these parameters are a function of the membrane

potential such that a high mitochondrial membrane potential

are di?icult to control. Uncontrolled uncoupling of mitochon

sloWs doWn metabolism and increases ROS formation and the

dria (i.e., dropping the mitochondrial membrane potential

uptake of Ca2+ into mitochondria.
The nanotubes conduct protons (i.e., open and uncouple

beloW about 100 mV) causes an inability to produce cellular

ATP, Which eventually leads to death.
Therefore, there is a need for safe, controllable, mitochon
drial uncouplers that can separeate the mitochondria respira
tion from the production of ATP, and thus safely produce the
desired effect, Without harming the individual.

50

mitochondria) only When a speci?c potential (i.e., breakover
voltage) is reached. This causes a drop in the mitochondrial

membrane potential that closes the nanotube proton channel,
in effect making the nanotubes self-rectifying. Therefore,
55

nanotubes can be designed to maintain a speci?c mitochon

60

drial membrane potential that can signi?cantly increase
metabolism Without the possibility of toxicity since the nano
tubes Will not function (act as proton channels) at a mitochon
drial membrane potential beloW the threshold for ATP pro
duction.

SUMMARY OF THE INVENTION

The present invention provides nanotubes Which safely
uncouple mitochondria, as the nanotubes can be prepared
such that the proton channel automatically shuts doWn When
an unsafe potential is reached.
The template method of forming nanotubes in one embodi
ment alloWs control of the dimensions of the nanotubes such
that the nanotubes can be designed to have any desired dimen

sions as speci?ed. By alloWing manipulation of siZe, particu
larly the inner diameter of the nanotubes (as explained

According to one embodiment, the dimensions of nano
tubes and the materials they are made from are manipulated to

accomplish safe mitochondrial uncoupling. For example,
65

When the diameter of the nanotubes is decreased, a smaller
diameter increases resistance and the conductance of protons

through the nanotubes (uncouples the mitochondria electron
transport from ATP production) only When the voltage

US 7,919,699 B2
These nanotubes that are highly effective for Weight-loss and

4
poly(vinyl alcohol), poly(esters), polyglycolide, polycapro
lactone, poly(ethylene oxide), poly(butylene terephthalate),

at the same time are substantially safe for use because they are

poly(hydroxyalkanoates), hydrogels, modi?ed poly(saccha

self-rectifying.

rides), starch, cellulose, and chitosan.

3
reaches threshold (the mitochondrial membrane potential).

In one embodiment, nanotubes can offer a safe and effec

In another embodiment a method of reducing the effects of

tive treatment for obesity and Weight management by increas

traumatic brain injury in an subject comprising administering

ing basal metabolism by increasing mitochondrial respira

a therapeutically effective amount of nanotubes to the subject,
Wherein the nanotubes are self-rectifying is disclosed.

tion.
In another embodiment a method of uncoupling mitochon
dria in a subject comprising administering nanotubes to the
subject in a therapeutically effective amount, Wherein the
nanotubes are self-rectifying is disclosed.
The nanotubes can be coated With a pKa reducing com
pound. The subject can be a mammal. The nanotubes have an
inner diameter suitable for uncoupling mitochondria. The
nanotubes have an inner diameter Which alloWs the nanotubes

The subject can be a mammal. The nanotubes have an inner

diameter designed for uncoupling mitochondria. The nano
tubes have an inner diameter Which alloWs the nanotubes to

self-rectify. The nanotubes comprise metals or polymers,
Wherein the metals are gold or silver, and Wherein the poly
mers are natural polymers or synthetic polymers. The poly
mers are preferably selected from the group consisting of

poly(vinyl alcohol), poly(esters), polyglycolide, polycapro
lactone, poly(ethylene oxide), poly(butylene terephthalate),

to self-rectify.
The nanotubes comprise metals or polymers, Wherein the

poly(hydroxyalkanoates), hydrogels, modi?ed poly(saccha

metal is gold or silver, and Wherein the polymers are natural

polymers or synthetic polymers. The polymers are preferably
selected from the group consisting of poly(vinyl alcohol),

20

In another embodiment, a method of reducing the effects of

poly(esters), polyglycolide, polycaprolactone, poly(ethylene
oxide), poly(butylene terephthalate), poly(hydroxyal

ageing in a subject comprising administering a therapeuti
cally effective amount of nanotubes to the subject, Wherein
the nanotubes are self-rectifying is disclosed.

kanoates), hydrogels, modi?ed poly(saccharides), starch,
cellulose, chitosan and combinations thereof.
In another embodiment, a method of decreasing reactive

rides), starch, cellulose, and chitosan.

25

The subject can be a mammal. The nanotubes have an inner

diameter designed for uncoupling mitochondria. The nano

oxygen species and decreasing detrimental loading of Ca2+
into mitochondria of a subject comprising administering

tubes have an inner diameter Which alloWs the nanotubes to

nanotubes to the subject in a therapeutically effective amount,
Wherein the nanotubes are self-rectifying is disclosed.

Wherein the metals are gold or silver, and Wherein the poly
mers are natural polymers or synthetic polymers. The poly
mers are preferably selected from the group consisting of

self-rectify. The nanotubes comprise metals or polymers,
30

The subject can be a mammal. The nanotubes have an inner

diameter designed for uncoupling mitochondria. The nano

poly(vinyl alcohol), poly(esters), polyglycolide, polycapro
lactone, poly(ethylene oxide), poly(butylene terephthalate),

tubes have an inner diameter Which alloWs the nanotubes to

self-rectify. The nanotubes comprise metals or polymers,
Wherein the metal is gold or silver, and Wherein the polymers
are natural polymers or synthetic polymers. The polymers are

35

poly(hydroxyalkanoates), hydrogels, modi?ed poly(saccha

40

In another embodiment, a pharmaceutical composition is
disclosed, Wherein the pharmaceutical composition com
prises nanotubes in a pharmaceutically acceptable carrier,
and Wherein the pharmaceutical composition is administered

preferably selected from the group consisting of poly(vinyl

alcohol), poly(esters), polyglycolide, polycaprolactone, poly
(ethylene oxide), poly(butylene terephthalate), poly(hy
droxyalkanoates), hydrogels, modi?ed poly(saccharides),

to an subject by (i) intravenous delivery, (ii) ingestion, (iii)

starch, cellulose, and chitosan.

particle bombardment via a gene gun, or (iv) patch or gel
application to the dermis.
In another embodiment a method of reducing the effects

In another embodiment, a method of reducing Weight in a

subject comprising administering a therapeutically effective
amount of nanotubes to the subject, Wherein the nanotubes
are self-rectifying is disclosed.

45

The subject can be a mammal. The nanotubes have an inner

diameter designed for uncoupling mitochondria. The nano
tubes have an inner diameter Which alloWs the nanotubes to

self-rectify. The nanotubes comprise metals or polymers,
Wherein the metal is gold or silver, and Wherein the polymers
are natural polymers or synthetic polymers. The polymers are

rides), starch, cellulose, and chitosan.

50

spinal cord injury in a subject comprising administering a
therapeutically effective amount of nanotubes to the subject,
Wherein the nanotubes are self-rectifying is disclosed.
In another embodiment, a method of reducing the effects of
stroke in a subject comprising administering a therapeutically
effective amount of nanotubes into the subject, Wherein the
nanotubes are self-rectifying is disclosed.

preferably selected from the group consisting of poly(vinyl

alcohol), poly(esters), polyglycolide, polycaprolactone, poly
(ethylene oxide), poly(butylene terephthalate), poly(hy
droxyalkanoates), hydrogels, modi?ed poly(saccharides),

BRIEF DESCRIPTION OF THE DRAWINGS
55

starch, cellulose, and chitosan.

manner in humans.

In another embodiment, a method of treating cancer in an

subject comprising administering a therapeutically effective
amount of nanotubes to the subject, Wherein the nanotubes
are self-rectifying is disclosed.

FIG. 1 shoWs tWo line graphs indicating that 2,4-DNP
increases metabolism and Weight loss in a dose-dependent
FIG. 2 shoWs bar graphs that illustrate mitochondrial
uncoupling as a result of administering 2,4-DNP increases

60

tissue sparing folloWing traumatic brain injury.
FIG. 3 shoWs bar graphs that illustrate post-injury admin

The subject can be a mammal. The nanotubes have an inner

diameter designed for uncoupling mitochondria. The nano

istration of 2,4-DNP increases tissue sparing folloWing spinal

tubes have an inner diameter Which alloWs the nanotubes to

cord injury (“SCI”).

self-rectify. The nanotubes comprise metals or polymers,
Wherein the metals are gold or silver, and Wherein the poly
mers are natural polymers or synthetic polymers. The poly
mers are preferably selected from the group consisting of

65

FIG. 4 shoWs electron microscopy photomicrographs of
isolated cortical mitochondrial folloWing the addition of
nanotubes (24 hour+histidine) that Were made in the presence

(left panel) or absence (right panel) of PEG.

US 7,919,699 B2
6

5
FIG. 5 shows a higher magni?cation of isolated cortical

A “therapeutically effective amount” or “pharmaceutically

mitochondrial following the addition of nanotubes (24 hour+

effective amount” means the amount of a compound that,
When administered to a mammal, is su?icient to uncouple
mitochondria, and/ or su?icient to decreasing reactive oxygen

histidine) that Were made in the presence of PEG.
FIG. 6 is a bar graph that shoWs that mitochondrial respi
ration is increased as a function of nanotube plating time (the

species and decreasing detrimental loading of Ca2+ into mito
chondria. A “therapeutically effective amount” or “pharma

longer the plating the time the smaller the diameter of the
nanotube) and/or the “doping” of the inside of the nanotube

ceutically effective amount” also means and amount su?i
cient for treating a disease and su?icient to effect such
treatment for the disease. The “therapeutically effective
amount” Will vary depending on the compound, the disease

With compounds of speci?c pKas.
FIG. 7 shoWs nanotubes manufactured by plating for 24 hrs
and/or “doped” With histidine do not impair mitochondrial

and its severity and the age, Weight, etc., of the mammal to be
treated. A “therapeutically effective amount” also may refer

ATP production.
FIG. 8 shoWs nanotubes manufactured by plating nano
tubes for 24 hrs and/or doping them With histidine increase
respirations less than nanotubes manufactured for shorter
times.
FIG. 9 shoWs that sequential additions of nanotubes results
in a saturation point being reached due the self-rectifying

to an amount su?icient to cause Weight loss.

“Pharmaceutically acceptable salt” refers to pharmaceuti
cally acceptable salts of scopolamine Which salts are derived
from a variety of organic and inorganic counter ions Well
knoWn in the art and include, by Way of example only,

sodium, potassium, calcium, magnesium, ammonium, tet

nature of the nanotubes.
FIG. 10 shoWs that nanotubes reduce mitochondrial mem

brane potential Which explains their ability to increase respi
ration, oxygen consumption and metabolism.

20

such as hydrochloride, hydrobromide, tartrate, mesylate,
acetate, maleate, oxalate and the like.
“Optional” or “optionally” means that the subsequently

FIG. 11 shoWs that nanotubes reduce reactive oxygen spe

cies production in isolated mitochondria.
FIG. 12 shoWs a line graph of days V. grams of Weight
gained upon administering nanotubes compared to adminis

raalkylammonium, and the like; and When the molecule con
tains a basic functionality, salts of organic or inorganic acids,

25

tering vehicle controls over a period of seven days.
FIG. 13 shoWs a line graph of days V. grams of Weight

described event or circumstance may, but need not, occur, and
that the description includes instances Where the event or
circumstance occurs and instances in Which it does not.
The term “individual” is a vertebrate, preferably a mam

mal. Mammals include, but are not limited to, humans,

gained upon administering nanotubes compared to adminis

rodents (i.e., mice, rats, and hamsters), farm animals, sport

tering vehicle controls over a period of 31 days.
30

DETAILED DESCRIPTION OF THE INVENTION

animals and pets. In a preferred embodiment, the individual is
a mammal and more preferably, a human.

As used herein, the term “introducing” means providing or
De?nitions

In accordance With this detailed description, the folloWing

35

administering to an individual. Methods of introducing nano
tubes into individuals are Well knoWn to those of ordinary
skill in the art and include, but are not limited to, injection,

abbreviations and de?nitions apply. It must be noted that as

intravenous or parenteral administration. Single, multiple,

used herein, the singular forms “a”, “an”, and “the” include
plural referents unless the context clearly dictates otherWise.
Thus, for example, reference to “compounds” includes a plu
rality of such compounds and reference to “the dosage”

continuous or intermittent administration can be effected.
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includes reference to one or more dosages and equivalents
thereof knoWn to those skilled in the art, and so forth.

The publications discussed herein are provided solely for
their disclosure prior to the ?ling date of the present applica
tion. Nothing herein is to be construed as an admission that

about 20 nm. In a preferred embodiment, these nanostruc
45

the present invention is not entitled to antedate such publica

tures are holloW tube-like and/ or solid Wire-like structures.

As used herein, the term “self-rectifying” refers to the
ability of the nanotubes to stop acting as a proton channel

tion by virtue of prior invention. Further, the dates of publi
cation provided may be different from the actual publication
dates, Which may need to be independently con?rmed.
Unless otherWise stated, the folloWing terms used in the

As used herein, the term “nanotube” includes structures
formed from various materials using a generally knoWn tem
plate method. Further, nanotubes include structures of vari
ous shapes having dimensions smaller than about 1000 nm,
preferably smaller than about 100 nm, more preferably
smaller than about 50 nm, and most preferably smaller than

once the mitochondrial membrane potential is loWered to a set
50

speci?cation and claims have the meanings given beloW:

threshold.
Nanotubes
The present invention relates to nanotubes used as mito

“Pharmaceutically acceptable carrier” means a carrier that

chondrial uncouplers-in the body. Previous mitochondrial

is useful in preparing a pharmaceutical composition that is
generally safe, non toxic and neither biologically nor other
Wise undesirable, and includes a carrier that is acceptable for

uncouplers, such as 2,4-DNP, are often toxic as they decrease

and/or stop the production ofATP in the body. The nanotubes
55

veterinary use as Well as human pharmaceutical use. “A phar

maceutically acceptable carrier” as used in the speci?cation
and claims includes both one, and more than one, such carrier.
“Treating” or “treatment” of a disease includes:

(1) preventing the disease, i.e., causing the clinical symptoms

60

of the present invention act are safe, as they do not adversely
affect production of ATP and utiliZe a different uncoupling
mechanism than the mechanism of the chemical uncouplers.
The presently disclosed nanotubes act as self-rectifying
proton channels across the mitochondrial inner membrane.
When the membrane potential reaches a certain point, the
nanotubes shut off the proton How. This mechanism is similar

of the disease not to develop in a mammal that may be
exposed to or predisposed to the disease but does not yet

to that of an electrical circuit, as the How across mitochondrial

experience or display symptoms of the disease,
(2) inhibiting the disease, i.e., arresting or reducing the devel

membranes folloWs the principles of Ohm’s laW. According
to Ohm’s laW, V (voltage):I (current) R (resistance) (i.e., if

opment of the disease or its clinical symptoms, or

(3) relieving the disease, i.e., causing regression of the disease

one reduces R, I Will increase). In the case of mitochondria,
the voltage is the separation of protons across the inner mem

or its clinical symptoms.

brane due to mitochondrial respiration (i.e., electron transport
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system activity) and the current is the How of protons back
across the inner membrane back into the matrix (i.e., How of

The use of nanotubes as proton channels in mitochondria

can circumvent the toxic side effects of chemical uncouplers

and safely increase metabolism (and promote Weight loss).

protons through the ATP synthase or nanotubes).
Under normal conditions, resistance (“R”) is set by the

Nanotubes act as high-conductance proton channels, mim

icking chemical uncouplers, Without substantially any chance

demand for ATP to be produced by mitochondria. In the case
of uncontrolled chemical uncoupling, resistance is a function

of toxicity. This can be accomplished by the use and manu
facturing of voltage-dependent nanotubes that act as effective
proton diodes and recti?ers in the mitochondrial membrane.
The nanotubes can conduct protons only When a speci?c

of the amount of uncoupler that is present. Thus, if the dosage
is too high, all resistance is abolished resulting in maximum
current ?oW. In the case of the presently disclosed nanotubes,
resistance can be adjusted by changing the inner diameter of
the nanotube and/or by “doping” the inside of the nanotubes
With compounds of speci?c pKas. The present nanotubes act

potential (i.e., breakover voltage) is reached Which causes the
nanotubes to act as proton channels Which Will reduce mito

chondrial membrane potential to a point that Will close the
nanotube proton channel.

as proton channels Which alloW protons to How back into the
matrix across the inner mitochondrial membrane due to the

As discussed supra, one reason that the present nanotubes

voltage (i.e., separation of charge) that is present.

are safe for use in the body is the mechanism of conducting

protons only When a speci?c potential (i.e., breakover volt

The How of protons can be controlled by increasing or

decreasing the inner diameter the nanotubes such that they

age) is reached. This characteristic of the nanotubes causes a

Will only alloW a How of protons only When a threshold

drop in the mitochondrial membrane potential that closes the
nanotube proton channel, in effect making the nanotubes
self-rectifying. Therefore, nanotubes can be designed to
maintain a speci?c mitochondrial membrane potential that
can signi?cantly increase metabolism, substantially Without

voltage is reached. By decreasing the inner diameter of the
nanotubes, the amount of voltage required to “push” protons
through the nanotube is increased, such that only When the

20

required voltage (or higher) is applied Will protons ?oW
through the nanotubes back into the matrix. This in effect
makes the nanotubes self-rectifying in that they Will not act as
proton channels once the mitochondrial membrane potential

the possibility of toxicity, because the nanotubes can be
designed to not function at a mitochondrial membrane poten
25

tial beloW the threshold for ATP production. Additionally, the
nanotubes (i.e., proton channels) can only function in the
mitochondria, because a proton gradient of about 120-220
mV does not exist anyWhere else in mammalian cells.

30

chondrial membrane potential that can signi?cantly increase
metabolism Without the toxicity associated With reducing
mitochondrial membrane potential beloW the threshold for
ATP production. Nanotube proton channels can function only

35

proton gradient of similar magnitude does not exist anyWhere

is loWered to a set threshold. This failsafe mechanism Will

activate regardless hoW many tubes are present, because they
Will only act as proton channels When the threshold voltage is

present.
Thus, the present nanotubes are safe to administer as mito
chondrial uncouplers, as they cause the mitochondnal uncou

Nanotubes can be designed to maintain a speci?c mito

pling to stop prior to any adverse effects.
The nanotubes, acting as proton channels, cause a reduc
tion in mitochondrial membrane potentials, Which in turn
increases basal metabolism, decreases reactive oxygen spe

at the mitochondria in the cells of in an individual because a

cies (“ROS”), and decreases detrimental loading of Ca2+ into

else in an individual’s cell.

mitochondria.

The inner diameter (“id”) of the nanotubes can be altered
until the desired conductance is realiZed. It is Well knoWn that

The present nanotubes may be made of metals, polymers,
semiconductors, carbons, and other materials. Preferably, the
nanotubes are made of any elemental metal that Will plate or

reducing the nanotube i.d. also reduces the conductance (in
40

coat the Walls of the template used, including, but not limited

to, gold, copper, platinum, nickel and silver. Most preferably,
the nanotubes are made of gold, as gold is inert and does not
cause any in?ammatory response in the body.
The nanotubes can be made from polymers. These poly

creases the resistance) of the channel to proton How in accor

dance With Ohms laW. See NishiZaWa M., et al., Metal Nano
tubule Membranes with Electrochemically Switchable [on

Transport Selectivity, Science (1995), 268, 700-702; Miller
45

mers can be natural or synthetic and can include poly(vinyl

S. A., et al., Electroosmotic?ow in template-prepared carbon
nanotube membranes, J.Am. Chem. Soc (2001). 123, 12335
12342; and Martin, C. R., Nanomaterials: A Membrane

alcohol), poly(esters), polyglycolide, polycaprolactone, poly
(ethylene oxide), poly(butylene terephthalate), poly(hy

Based Synthetic Approach, Science (1994), 266, 1961-1966.

droxyalkanoates), hydrogels, modi?ed poly(saccharide)s

nanotubes can be adjusted and/or increased by using com

such as starch, cellulose, and chitosan.
Different characteristics of the nanotubes, such as the
effective half-life (i.e., hoW long the nanotube Will be stable in

Further, the proton conductance and selectivity of the
50

acids. These amino acids can be incorporated into the inner

Walls of the nanotubes during template synthesis. Depending

the body), can be altered by changing the percent composition

on the chemical properties of the amino acids, nanotubes that
are highly-selective for protons in addition to being pH sen

of the different polymers to achieve a desired effect. See

Martin C. R., et al., Materials science: Expanding the
Molecular Electronics Toolbox, Science, 2005 July 1, 309
(5731):67-8; Kohli, P., et al., Smart Nanotubesfor Biotech
nology, CurrentPharmaceutical Biotechnology, 2005 Febru
ary, 6(1):35-47; Martin C. R., Nanomaterials: A Membrane
Based Synthetic Approach, Science (1994), 266, 1961 -1 966;
and Martin C. R., The Emerging Field ofNanotube Biotech
nology, Nature RevieWs Drug Discoveries (2003), 2 29-37.
Copolymers of poly(ester)s based on polylactide, polygly

55

and poly(butylene terephthalate) can also be used to make the
nanotubes. The poly(esters) can be based on polylactide.

sitive can be created.

Generally, a pH difference of about 0.5 exists across the
inner mitochondrial membrane. When the interior surface of

the nanotubes is coated (i.e., “doped”) With compounds of
speci?c pKa such that the nanotube shuts off When this pH
60

colide, and polycaprolactone can also be used to make the

nanotubes. Multiblock copolymers of poly(ethylene oxide)

pounds of speci?c pKa including speci?c chemisorbed amino

65

gradient reaches a certain level such that the compound Will
no longer be protonated and cease to conduct protons. This
acts as a second failsafe device, in addition to controlling
proton conductance. Based on the pH gradient across the

mitochondrial inner membrane, any compound With a pKa in
the range of4 to 5 (in H2O at ~37° C.) and that has a small
enough molecular Weight that it can ?t into the nanotube,
Would be ideal for this application. lon selectivity can also be

US 7,919,699 B2
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adjusted by doping the inside of the nanotubes With com
pounds of the opposite charge of the ion selected.
Preparation of Nanotubes

umes. The membrane is kept in the SnCl2 and tri?uoroacetic
acid solution for about 30-60 minutes. The solution is then
drained off and the membrane is immersed in methanol. The

A template method of forming the nanotubes generally
includes (a) immersing a template membrane into methanol,
(b) immersing the template membrane into a solution having

immersion of the membrane in methanol is to remove any
residual SnCl2 or tri?uoroacetic acid. The membrane is then
immersed in an aqueous ammonical AgNO3 solution. The

SnCl2 and tri?uoroacetic acid, (c) immersing the template
membrane in methanol tWice, (d) immersing the template

membrane is placed in a solution containing substantially
equal volumes of Na2SO3, NaHCO3, HCOOH, and a com
mercial gold plating solution. The solution should be main

membrane in an aqueous ammonical AgNO3 solution or any
aqueous solution containing the material you Wish to use for

tained at a temperature of about 5 ° C. The membranes are kept

plating of the membrane, (e) immersing the template mem
brane in methanol, (f) placing the template membrane in a
gold-plating bath, the gold-plating bath having commercial

in the gold-plating solution for 3, 6, 9 or 24 hours. The inner
diameter of the tubes changes With the plating time. After the
respective amount of time, the solution is drained-off and

gold plating solution, (g) adjusting the pH of the gold-plating

CH2Cl2 or other similar solvent is added to dissolve the mem

bath to about 10 by drop-Wise addition of HZSO4 While stir

brane. The solution is then centrifuged to separate aggregated
nanotubes. The solution is then removed leaving the aggre
gated nanotubes behind. PEG is added to the aggregated

ring, (h) placing the template membrane in the gold-plating
bath for different periods of time to obtain holloW tube-like
structures of different inside diameters. CH2Cl2 is added to
dissolve the membrane.
In one embodiment, the template method of forming the

nanotubes includes (a) immersing a template membrane into
methanol for about 2-10 minutes, (b) immersing the template
membrane into a solution having SnCl2 and tri?uoroacetic
acid for about 30-60 minutes, (c) immersing the template
membrane in methanol tWice for about 1-5 minutes each time,
(d) immersing the template membrane in an aqueous
ammonical AgNO3 solution for about 2-10 minutes, (e)
immersing the template membrane in methanol for about
2-10 minutes, (f) placing the template membrane in a gold
plating bath at a temperature of about 2-100 C., the gold

nanotubes such that the PEG coats the nanotubes causing the

aggregated nanotubes to separate such that substantially indi
20

(i.e., mixed vigorously using a genie vortexer or other similar
mixer) to aid the coating of the nanotubes With PEG thereby
increasing the availability of the nanotubes in solution. The
25

mixture is then ?ltered to remove any particulate matter. The

?ltered nanotubes are then pelleted by centrifugation, the
supernatant removed and the pellet re-suspended in ethanol to
remove excess PEG. The nanotubes are thenpelleted again by

centrifugation, the supernatant removed and the pellets are
30

re-suspended in sterile Water and stored at about 40 C.
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The plated membranes obtained from the method
described above can then be placed in a solution of histidine
(or any compound one Wishes to us to dope the inside of the
nanotubes). The plated membranes are left in the histidine
solution for 24 hours to alloW the histidine to coat the inner

plating bath having commercial gold plating solution, Which

typically includes Na2SO3, formaldehyde, and NaHCO3, (g)
adjusting the pH of the gold-plating bath to about 10 by

drop-Wise addition of H2SO4 While stirring, (h) placing the
template membranes in the gold-plating bath for different

vidual nanotubes coated With PEG are available in Water or
similar solvent as a solution. The mixture is then vortexed

periods of time to obtain holloW tube-like structures of dif
ferent inside diameters. CH2Cl2 is added to dissolve the mem
brane.

Walls of the plated membranes having the nanotubes. The
coated membranes can be removed and placed in CH2Cl2 and

Preferably, in another embodiment, the template method of
forming the nanotubes includes (a) immersing a template
membrane into methanol for about 2-10 minutes, preferably
for about 5 minutes, (b) immersing the template membrane

to the resultant solution Which Will coat the outside of the
nanotubes making them soluble. The PEG solution can be
centrifuged so that the nanotubes settle at the bottom. The

sonicated, so as to dissolve the membrane. PEG can be added
40

PEG solution can be removed so that the nanotubes can be

collected. Ethanol (“EtOH”) can be added alloWing the tubes

into a solution having about 0.025 M SnCl2 and 0.07 M

tri?uoroacetic acid for about 30-60 minutes, preferably for

about 45 minutes, (c) immersing the template membrane in

45

methanol tWice for about 1-5 minutes each time, preferably

for about 2.5 minutes each time, (d) immersing the template
membrane in a 0.029 M aqueous ammonical AgNO3 solution

for about 2-10 minutes, preferably for about 5 minutes, (e)
immersing the template membrane in methanol for about
2-10 minutes, preferably for about 5 minutes, (f) placing the

50

ci?c chemisorbed amino acids. These amino acids can be

gold-plating bath having commercial gold plating solution,
55

dehyde, and 0.025 M NaHCO3, (g) adjusting the pH of the

H2SO4 While stirring, (h) placing the template membranes in
the gold-plating bath for different periods of time to obtain
60

membrane (e.g., from SterlitechTM Corporation) is immersed
in methanol for 5 minutes. Substantially all of the methanol is
Which is about 0.025 M SnCl2 and about 0.07 M tri?uoroace
tic acid. Both the chemicals should be added in equal vol

nanotubes is doped With compounds of speci?c pKa, that the
nanotubes shut off When a speci?c pH is reached.
Any Weak acid that has a pKa of4-5 in H2O at about 370 C.
and has molecules that can penetrate the id. of the nanotubes,

CH2Cl2 is added to dissolve the membrane.
In another embodiment, a polycarbonate track etched
drained off and the membrane is immersed in a solution

incorporated into the inner Walls of the nanotubes during
template synthesis. Depending on the chemical properties of
the amino acids nanotubes that are highly-selective for pro
tons in addition to being pH sensitive can be created. Gener
ally, a pH difference of about 0.5 exists across the inner
mitochondrial membrane. When the interior surface of the

gold-plating bath to about 10 by drop-Wise addition of 0.5 M
holloW tube-like structures of different inside diameters.

obtain histidine coated nanotubes.
PEG is added to the outside of the nanotubes in order to
alloW them to become soluble in solution, prior to ?ltration.
Nanotubes that are manufactured in the absence of PEG do
not make it through the ?ltration process.
Further, the proton conductance of the nanotubes can be

adjusted by using compounds of speci?c pKa including spe

template membrane in a gold-plating bath at a temperature of
about 2-100 C., preferably at a temperature of 50 C., the

Which typically includes 0.127 M Na2SO3, 0.625 M formal

to be suspended in a sterile medium. The solution can be
drained off after centrifuging and EtOH can be added to

can be used as proton conductance adjusting compounds. In a
65

preferred embodiment, these proton conductance adjusting
compounds are selected from the group consisting of aspar

ate, glutamate, and combinations thereof.

